US 7,615,622 B2
	Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor VIII
Evgueni L. Saenko, Gaithersburg, Md. (US); and Andrey G Sarafanov, Rockville, Md. (US)
Assigned to University of Maryland, Baltimore, Baltimore, Md. (US)
Appl. No. 10/472,516 PCT Filed Jan. 11, 2002, PCT No. PCT/US02/00583 § 371(c)(1), (2), (4) Date May 26, 2004, PCT Pub. No. WO02/060951, PCT Pub. Date Aug. 08, 2002.
Claims priority of provisional application 60/260904, filed on Jan. 12, 2001.
Prior Publication US 2004/0248785 A1, Dec. 09, 2004
Int. Cl. C07H 21/02 (2006.01); C07H 21/04 (2006.01); C07K 1/00 (2006.01)

U.S. Cl. 536—23.5  [536/23.1; 530/350]

3 Claims

1. A isolated polynucleotide encoding a mutant factor VIII polypeptide, wherein said mutant factor VIII polypeptide consists of a human or porcine factor VIII polypeptide containing at least one nonconservative amino acid substitution at a position corresponding to an amino acid selected from the group consisting of Lys (380), Lys (512), Lys (523), Lys (556), Lys (570), Arg (571), and Lys (659) of SEQ ID NO: 5, and wherein said mutant factor VIII polypeptide exhibits procoagulant activity and reduced heparan sulfate proteoglycan (HSPG)-dependent, receptor-independent clearance.